You are here

  • Home
  • Archive
  • Volume 92, Issue 5
  • It is safe to switch therapy from interferon beta or glatiramer acetate to oral therapy in patients with relapsing multiple sclerosis with stable disease

Article Text

Article menu
Download PDFPDF
Editorial commentary
It is safe to switch therapy from interferon beta or glatiramer acetate to oral therapy in patients with relapsing multiple sclerosis with stable disease

https://doi.org/10.1136/jnnp-2020-325684

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors NK-H solely authored this editorial.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests NK-H has within 2 years received support for participation in congresses and symposia by SG.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles